Anti-CD62L Antibody (DREG-200) 

Anti-CD62L Antibody (DREG-200) is a human monoclonal antibody targeting CD62L/L-selectin. Anti-CD62L Antibody (DREG-200) binds to residues 45, 46 and 47 of L-selectin, and blocks L-selectin-mediated interactions, neutrophil rolling, adhesion, aggregation, secondary anchoring, as well as leukocyte rolling on ligands. Anti-CD62L Antibody (DREG-200) reduces myocardial necrosis, coronary endothelial dysfunction, and neutrophil migration driven by neutrophil microparticles. Anti-CD62L Antibody (DREG-200) exerts cardioprotective effects in feline models. Anti-CD62L Antibody (DREG-200) can be used in studies related to myocardial ischemia-reperfusion injury. The recommended isotype control is Mouse IgG1 kappa (HY-P99977)^[1][2][3].

Mouse IgG1 kappa

Mouse IgG1 kappa, Isotype Control

Human

Anti-CD62L Antibody (DREG-200) (15 μg/10⁶ neutrophils; 0.5-1 h) blocks the enhanced IL-8-induced chemotaxis of isolated human peripheral blood neutrophils by L-NAME (HY-18729A), and inhibits the ability of L-NAME-induced human neutrophil-derived microparticles to enhance IL-8-induced chemotaxis of isolated human peripheral blood neutrophils^[1].
Anti-CD62L Antibody (DREG-200) (at saturated concentration; incubated at 4°C for 30 min) detects the expression of L-selectin on human neutrophil-derived microparticles^[1].
Anti-CD62L Antibody (DREG-200) (40 μg/mL; 30 min) specifically binds to unstimulated feline neutrophils^[2].
Anti-CD62L Antibody (DREG-200) (10-40 μg/mL; 5 min PMN preincubation, 20 min incubation at 4°C) inhibits the adhesion of unstimulated feline polymorphonuclear leukocytes (PMN) to ischemic/reperfused feline coronary vascular endothelium in a concentration-dependent manner, while exerting no effect on their adhesion to normal endothelium^[2].
Anti-CD62L Antibody (DREG-200) blocks L-selectin-mediated rolling of primary human blood lymphocytes on immobilized PSGL-1-Fc under flow conditions^[3].
Anti-CD62L Antibody (DREG-200) blocks L-selectin-mediated rolling of Jurkat cells on immobilized PSGL-1-Fc, E-selectin-Fc, PNAd and sLex-PAA under flow conditions^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-CD62L Antibody (DREG-200) (1 mg/kg; i.v.; single bolus injection; 10 minutes before reperfusion) significantly attenuates myocardial necrosis by 56% and reduces neutrophil accumulation in ischemic/reperfused cat myocardium, while preserving coronary endothelial function^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

6402  [NCBI]

P14151

CD62L

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Nolan S, et al. Nitric oxide regulates neutrophil migration through microparticle formation. Am J Pathol. 2008;172(1):265-273.  [Content Brief]

  [2]. Ma XL, et al. Monoclonal antibody to L-selectin attenuates neutrophil accumulation and protects ischemic reperfused cat myocardium. Circulation. 1993;88(2):649-658.  [Content Brief]

  [3]. Riese SB, et al. Heterotropic modulation of selectin affinity by allosteric antibodies affects leukocyte rolling. J Immunol. 2014;192(4):1862-1869.  [Content Brief]